Related Experiment Video
Updated: Jan 13, 2026

Analyzing the Functions of Mast Cells In Vivo Using 'Mast Cell Knock-in' Mice
Published on: May 27, 2015
The Putative Role of Mast Cells in Oral Leukoplakia-A Systematic Review and Meta-Analysis
Nikita Kashyap1, Achla Bharti1, Mala Kamboj1
1Department of Oral and Maxillofacial Pathology and Microbiology, Post Graduate Institute of Dental Sciences, Pandit BD Sharma University of Health Sciences, Rohtak, Haryana, India.
Background:
Mast cells are believed to contribute to inflammation-associated carcinogenesis, but their specific role in the development of oral leukoplakia (OLK) and its progression to oral squamous cell carcinoma (OSCC) remains uncertain. This systematic review and meta-analysis aimed to determine whether mast cell density differs among normal oral mucosa (NOM), OLK, and OSCC.
Methods:
A comprehensive literature search was conducted in PubMed, Scopus, Web of Science and Embase along with Google Scholar for studies that reported mast cell counts in OLK, OSCC, and NOM published up to September 30, 2025. Data were extracted, and the mean difference was calculated. Risk of bias was assessed using the JBI critical appraisal tool, and meta-analysis was performed using MetaAnalysisOnline.com.
Results:
Thirty-four studies were included for qualitative and 26 contributed to quantitative data synthesis. The studies opined that mast cells were highest in OSCC, followed by OLK and NOM. Mast cell density was higher in OSCC than in OLK; however, the difference was not significant. A random-effects model revealed a significant increase in mast cell density in OLK than NOM (p < 0.0001) and OSCC than NOM (p = 0.0055); however, when OLK was compared with OSCC, the difference was not significant (p = 0.2865).
Conclusion:
The existing data validate that mast cells were increased in oral leukoplakia, indicating their potential involvement in early oral carcinogenesis; however, future studies focusing on the prognostic value of mast cells in oral leukoplakia are warranted.
Trial Registration:
PROSPERO number: CRD42024533723.
More Related Videos
08:25An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation
Published on: April 27, 2021
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024